Both CD68+ve and CD163+ve TAMs were more abundant in metastatic compared to non-metastatic melanomas [16,17], and in malignant compared to benign melanocytic lesions [18], a finding which has been associated with tumor progression and metastasis aas well as poor clinical outcome. Here, CD163 is linked to neoplasm.